<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Broe | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/congaspark16/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/congaspark16/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Broe.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">38a3281c0048f5ff17629478e5f13ad0</guid>
				<title>Broe posted an update: Erythema and pain were high in derma roller group in compare [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/40212/</link>
				<pubDate>Thu, 06 Feb 2025 14:32:50 -0800</pubDate>

									<content:encoded><![CDATA[<p>Erythema and pain were high in derma roller group in compare to intradermal.</p>
<p> Derma roller technique is more convenient and easy to perform, especially when the availability of a trained person to carry out intradermal injection is not feasible, it gives satisfactory results. It is also beneficial in needle phobic and apprehensive patients.&hellip;<span class="activity-read-more" id="activity-read-more-40212"><a href="http://www.nationalboardinstitute.com/activity/p/40212/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">7c34af8fb16330cc8c70b3eb1ee231dc</guid>
				<title>Broe posted an update: To stratify the prognosis of patients with programmed cell [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/38640/</link>
				<pubDate>Tue, 04 Feb 2025 12:12:12 -0800</pubDate>

									<content:encoded><![CDATA[<p>To stratify the prognosis of patients with programmed cell death-ligand 1 (PD-L1) ≥ 50% advanced non-small-cell lung cancer (aNSCLC) treated with first-line immunotherapy.</p>
<p> Baseline clinical prognostic factors, the neutrophil-to-lymphocyte ratio (NLR), PD-L1 tumour cell expression level, lactate dehydrogenase (LDH) and their combination w&hellip;<span class="activity-read-more" id="activity-read-more-38640"><a href="http://www.nationalboardinstitute.com/activity/p/38640/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">56ca1e03cb7b6d87f6aff5745337efaf</guid>
				<title>Broe posted an update: Here, we report the coding-complete genome sequences of nine [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36889/</link>
				<pubDate>Sun, 02 Feb 2025 12:27:43 -0800</pubDate>

									<content:encoded><![CDATA[<p>Here, we report the coding-complete genome sequences of nine clinical severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and their mutations. The samples were collected from nine Bangladeshi coronavirus disease 2019 (COVID-19) patients. We have identified the E484K escape mutation and the S359T mutation within the spike protein&hellip;<span class="activity-read-more" id="activity-read-more-36889"><a href="http://www.nationalboardinstitute.com/activity/p/36889/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">a4bd8ed4b81f0e5307061b64e262210c</guid>
				<title>Broe posted an update: In May 2018, the World Health Organization (WHO) called for [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/35018/</link>
				<pubDate>Fri, 31 Jan 2025 12:35:10 -0800</pubDate>

									<content:encoded><![CDATA[<p>In May 2018, the World Health Organization (WHO) called for the elimination of cervical cancer. To monitor this Initiative, we examined cervical cancer incidence and mortality in the Latin America and Caribbean (LAC) region using GLOBOCAN 2018, Cancer Incidence in Five Continents Series, and the World Health Organization Mortality Database. We&hellip;<span class="activity-read-more" id="activity-read-more-35018"><a href="http://www.nationalboardinstitute.com/activity/p/35018/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">726ee2db0f491df060ed8dd1e5ee4445</guid>
				<title>Broe posted an update: These findings indicate that miR-452-5p may act as a [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/28317/</link>
				<pubDate>Tue, 28 Jan 2025 11:04:00 -0800</pubDate>

									<content:encoded><![CDATA[<p>These findings indicate that miR-452-5p may act as a potential therapeutic target and clinical response biomarker for CRC.</p>
<p>To conclude, miR-452-5p expression is up-regulated in CRC, which promotes the progression of CRC by activating the miR-452-5p-PKN2/DUSP6-c-Jun positive feedback loop. These findings indicate that miR-452-5p may act as a&hellip;<span class="activity-read-more" id="activity-read-more-28317"><a href="http://www.nationalboardinstitute.com/activity/p/28317/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">04c0dce374c740b4ec411285b7f6fa06</guid>
				<title>Broe became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/28298/</link>
				<pubDate>Tue, 28 Jan 2025 11:00:16 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>